Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of equine tetanus immunoglobulin F(ab′)2 in mild trauma patients
ChiCTR2500105791Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Kunming Medical University
- Start
- Jul 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of equine tetanus immunoglobulin F(ab′)2 in Tetanus, sponsored by The Sixth Affiliated Hospital of Kunming Medical University. Primary endpoint: Incidence of local and systemic adverse events and treatment-related adverse events within 21 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
equine tetanus immunoglobulin F(ab′)2
03
Conditions
Tetanus
Beyond the preview
Go deeper on ChiCTR2500105791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105791.